VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask’s VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.
VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask’s VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.